Jimmy Van den Eynden

We're recruiting a PhD student to perform research on the fascinating crossroads between engineering and cancer genomics. Joint PhD project with @jvdesomp @crighent @UGent_HSR @ugent_fge ugent.be/en/work/scient…

@elonmuskADO 35 🤷🏻‍♂️

Congratulations to Sofie Hoogstoel for winning the best poster prize at the NAV 2024 anatomy conference in Lunteren. Her poster demonstrated the potential of whole-body donors in studying early carcinogenesis.

Honored to have hosted @RuthPalmerALK and @bengtHallberg for 2 interesting @crighent seminars last week @ugent_fge. Many fruitful scientific discussions with @SpelemanLab. Very excited about this new collaboration and convinced we will make a difference in #neuroblastoma research

Happy to share our latest study, where we use UV light to map protein-DNA interactions using a capture based CPD-seq method. This represents a massive enrichment in CPDs over previous genome-wide studies nature.com/articles/s4146…

Particularly liked how they demonstrate monoallelic loss of the HLA allele with the best neoantigen presenting capacity!

Genetic immune escape is present in minimally 25% of tumors and this prevalence is remarkably similar between primary and metastatic tumors. I wrote @NatureGenet News and Views article on this nice work from @fran_mj88 and colleagues from the Cuppen lab. nature.com/articles/s4158…

@fran_mj88 @Nature @NatureGenetics Congrats! I wrote a News & Views article about your work. rdcu.be/dbPAa Particularly liked how you demonstrate monoallelic loss of the HLA allele with the best neoantigen presenting capacity!

🚨 Delighted to share our back-to-back publications in @Nature (nature.com/articles/s4158…) and @NatureGenetics (nature.com/articles/s4158…)🚨. In these publications we unravel the pan-cancer immunogenomics differences between primary and metastatic tumors. Thread below🧵👇

Based on an extensive benchmarking effort we recommend Optitype and HLA-HD for MHC class I and class II genotyping from NGS data, respectively. bmcgenomics.biomedcentral.com/articles/10.11…

Congratulations to @JoachimSiaw for receiving the @crighent Young Investigator Proof-Of-Concept project funding. The funding will allow him to evaluate the therapeutic efficacy of RUVBL inhibitors in #Neuroblastoma mice models. crig.ugent.be/en/news/crig-y…

@CR_AACR @xsliu9 @WangShxiang As we have demonstrated in a doi.org/10.1158/0008-5…, we believe this is another illustration of the misinterpretation of HLA affinity signals in cancer genomics.

#ICYMI: Wu et al. build a new method for quantifying neoantigen mediated negative selection in individual #CancerPatients and describe a #biomarker for predicting clinical response to cancer #immunotherapy. bit.ly/3QYWLrw @xsliu9 @WangShxiang

4.Citing your own unpublished preprints as scientific facts is a very questionable scientific practice!

3.Naïve data filtering = asking for problems. When only 10% of mutations are neoantigenic, removing samples without these mutations is problematic in tumors with low TMB.

In a Letter to The Editor of @CR_AACR we demonstrate that the immunoediting signals perceived by Wu et al in bit.ly/3QYWLrw are false. doi.org/10.1158/0008-5… Another illustration of the misinterpretation of HLA affinity signals in cancer genomics! Our main concerns:

ALK fusion oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression. Congratulations to Tzu-Po Chuang, Jonatan Gabre, Bengt Hallberg and colleagues with the publication of this important work in PNAS today pnas.org/doi/10.1073/pn…

Excited to formally kickoff the European #PerImmune project with @WimCeelen and colleagues!

Together with @fspelema & @goossens_lab we are looking for a motivated postdoc to study the tumour-immune microenvironment in neuroblastoma at @ugent & @VIBLifeSciences Deadline for applications is 28th Feb. Apply here: career5.successfactors.eu/sfcareer/jobre…

In addition to the funding @joachimsiaw received from AGFond and @komop_tgkanker and @FWOVlaanderen PhD fellowships from @TomLuijts and Arne Claeys, this has been a very successful year for the lab! ccgg.ugent.be

Exciting scientific times at CCGG lab with recently obtained funding from @FWOVlaanderen and @Stkstichting for our #neuroblastoma research (collaboration with @SpelemanLab and Palmer lab) and from @crighent for our research on mutant skin clones (collaboration with @IHoorens).